Background: Although in vitro breast cancer models have demonstrated a role for protein kinase C (PKC) a and d isoforms in endocrine insensitivity and resistance respectively, there is currently little clinical evidence to support these observations. Aims: To define the pattern of PKC a and d expression using breast cancer cell lines, with and without endocrine resistance, and also breast cancer samples, where expression can be correlated with clinicopathological and endocrine therapy outcome data. Methods: PKC isoform expression was examined in tamoxifen responsive, oestrogen receptor positive (ER + ), ER + acquired tamoxifen resistant (TAM-R) and oestrogen receptor negative (ER 2 ) cell lines by western blotting and immunocytochemical analysis. PKC isoform expression was then examined by immunohistochemistry in archival breast cancer specimens from primary breast cancer patients with known clinical outcome in relation to endocrine response and survival on therapy.
Background: Although in vitro breast cancer models have demonstrated a role for protein kinase C (PKC) a and d isoforms in endocrine insensitivity and resistance respectively, there is currently little clinical evidence to support these observations. Aims: To define the pattern of PKC a and d expression using breast cancer cell lines, with and without endocrine resistance, and also breast cancer samples, where expression can be correlated with clinicopathological and endocrine therapy outcome data. Methods: PKC isoform expression was examined in tamoxifen responsive, oestrogen receptor positive (ER + ), ER + acquired tamoxifen resistant (TAM-R) and oestrogen receptor negative (ER 2 ) cell lines by western blotting and immunocytochemical analysis. PKC isoform expression was then examined by immunohistochemistry in archival breast cancer specimens from primary breast cancer patients with known clinical outcome in relation to endocrine response and survival on therapy.
Results: ER
+ breast cancer cell lines expressed considerable PKC-d but barely detectable levels of PKC-a, whereas ER 2 cell lines expressed PKC-a but little PKC-d. ER + acquired TAM-R cell lines expressed substantial levels of both PKC-a and d. In clinical samples, high PKC-d expression correlated to endocrine responsiveness whereas PKC-a expression correlated to ER negativity. PKC-d was an independent predictor of duration of response to therapy. Patients showing a PKC-d + /PKC-a 2 phenotype had a six times longer endocrine response than patients with the PKC-d + / PKC-a + phenotype (equating to tamoxifen resistance in vitro). Conclusions: Levels of PKC-a and d expression appear to be indicative of response to anti-oestrogen therapy and could be useful in predicting a patient's suitability for endocrine therapy.
A nti-hormone therapies such as tamoxifen are widely used to treat breast cancer patients. 1 A small but significant number of patients receiving tamoxifen however will not respond or will develop resistance. 2 3 Many mechanisms have been suggested which may play a role in tamoxifen resistance but the mechanisms have not yet been fully elucidated. [4] [5] [6] [7] Although rapid progress is being made in understanding the biology of oestrogen receptor (ER) function, the only predictive markers for endocrine therapy that currently yield sufficient levels of evidence to be recommended for routine practice, are ER and progesterone receptors, and to a lesser extent HER-2 status. 1 Better ways of predicting which patients are suitable for endocrine therapy would prove useful in the fight against breast cancer. Expression of the signal transduction molecule, protein kinase C (PKC) is increased in breast cancer models of poor prognosis; for example, ER 2 cell lines express significantly more PKC than ER + cell lines. 8 9 However, multiple isoforms of PKC exist, with variation in their expression profile and mechanism of activation. [10] [11] [12] We have previously shown that ER + MCF-7 cell lines have high PKC-d and low PKC-a expression, whereas ER 2 MDA-MB-231 cells have high PKCa and low PKC-d expression. A wealth of literature now support these observations [13] [14] [15] [16] linking PKC-a expression to loss of ER expression and adverse cellular features, 13 15 and there is also emerging data that PKC-d expression can relate to loss of endocrine sensitivity in vitro. 17 These studies did not however investigate the effect of PKC-d expression on clinical outcome. Moreover, a recent clinical study showed PKC-a to be decreased in advanced breast cancer samples, 18 suggesting that laboratory observations may not translate to the clinic.
We have therefore established cell line models of tamoxifen resistance, 19 20 and used these models and well-characterised clinical specimens 21 22 with known response to endocrine therapy, to study PKC expression. We have shown that PKC-a and d may prove useful in predicting whether patients will respond or not to endocrine therapy.
MATERIALS AND METHODS

Cell culture
For experimental purposes ER + and ER 2 breast cancer cell lines were grown in phenol red-free RPMI medium supplemented with 5% activated charcoal stripped, steroid depleted fetal calf serum (ssFCS), 200 mM glutamine and antibiotics (10 IU/ml penicillin, 10 mg/ml streptomycin). Acquired TAM-R cell lines were established by culturing MCF-7 19 or T47D 20 cells in 10 27 M 4-hydroxy-tamoxifen for 6 months. These resistant cells overexpress EGF receptor, 19 and have enhanced MAPK signalling, 20 23 24 enhanced growth characteristics, 20 25 and increased Src activity versus their parental lines. 26 Western analysis Cells were lysed in buffer (4˚C) and acetone precipitated as previously described. 27 Protein (40 mg) was run on an 8% SDS-PAGE gel and blotted onto membranes. Non-specific binding was blocked with 5% non-fat milk in Tris-buffered saline (TBS; 10 mM Tris pH 7.5, 100 mM NaCl) containing 0.1% Tween-20. Primary monoclonal antibodies (Transduction Laboratories; a = IgG 2b clone 3, d = IgG 2b clone 14) were diluted according to manufacturer's instructions in TBS containing 1% bovine serum albumin (BSA), and incubated with the blot for 3 hours Abbreviations: AP-1, activator protein-1 complex; BSA, bovine serum albumin; DAB, diamino benzidine-tetrahydrochloride; EGF, epidermal growth factor; ER, oestrogen receptor; ERK2, extracellular signal-regulated kinase 2; HR, hazard ratio; MAPK, mitogen activated protein kinase; NHS, normal human serum; PBS, phosphate buffered saline; PKC, protein kinase C; TAM-R, tamoxifen resistant; TBS, Tris buffered saline at 22˚C, then overnight at 4˚C. The membrane was washed 665 min in TBS-Tween before incubating in secondary antibody (mouse horseradish peroxidase conjugated, Amersham International, 1 hour). The blot was washed 665 min in TBSTween; antibody binding was detected using the SuperSignal WEST DURA chemiluminescence system (Pierce).
Immunocytochemical examination of paraffin embedded cells
Cells were concentrated by centrifugation (1000 g for 5 min), then fixed in 4% formal-saline for 4 h. Fixed cells were transferred to agar solution to form solid pellets and embedded in paraffin-wax. Pellets were cored and assembled in triplicate using a tissue arrayer (Beecher Instruments), forming a composite pellet array which was sectioned (5 mm) onto Superfrost slides before assaying as below. Using the clinically defined HScore cut offs to define positivity, sections were assessed for PKC-a and PKC-d expression as detailed below.
Immunohistochemical examination of clinical samples
Formal-saline (4%) fixed, paraffin-embedded breast cancer tissue was available from 70 primary breast cancer patients, who subsequently received systemic endocrine therapy (primarily using tamoxifen) as detailed previously, 21 either for locally-advanced primary carcinoma or metastatic disease. Data was available regarding the patients' quality of endocrine response (25 responders (complete, partial and static disease) vs 45 progressive disease) assessed according to UICC criteria at 6 months, duration of endocrine response and survival time on endocrine therapy, ER status (ie, ER 2 , n = 27; ER + , n = 43), histological grade (grade 1 or 2, n = 29; grade 3, n = 40), site of disease (locally advanced, n = 27; other sites, n = 42) and menopausal status (premenopausal, n = 21; postmenopausal, n = 48).
Immunostaining of clinical material (and cell pellet arrays) was done by dewaxing paraffin sections (5 mm) in xylene and rehydration through a decreasing alcohol concentration series. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide solution (5 min) and antigens retrieved by previously optimised procedures (PKC-d: 0.02% protease E in PBS at 37˚C; PKC-a: microwaving in citrate buffer) followed by water and PBS rinses. Sections were blocked in normal human serum (NHS, 20%, 15 min) and then incubated for 18 h with 16.5 mg/ ml anti-PKC-d (IgG 2b clone 14, Transduction Laboratories, preincubated with NHS for 30 min) or 2 mg/ml anti-PKC-a (IgG 1 clone 4, Upstate Biotechnology) monoclonal antibody prepared in PBS. Sections were washed in PBS (3 min), then in ''DPC''-detergent containing buffer (265 min). Biotinylated anti-mouse immunoglobulin (1:40 dilution in PBS containing 1% BSA) was applied for 60 min. After washing, a peroxidaselabelled streptavidin immunodetection system was employed (SuperSensitive Concentrated Detection Kit, Biogenex) using DAB/hydrogen peroxide chromogen (ER-ICA kit, Abbott Laboratories) and methyl green counterstaining.
In the absence of any obvious cut-off point for immunostaining, patients were classified as PKC-a or d positive using the median of the tumour epithelial HScore immunostaining index for each marker, 28 such that PKC-a positive = HScore .110 and PKC-d positive = HScore .120. Relationships between PKC status and clinicopathological parameters were examined using x 2 tests. Univariate analysis of survival from initiation of therapy and duration of endocrine response was performed using the KaplanMeier method and log rank test. Multivariate analysis was performed using a Cox proportional hazards model, controlling for PKC-a expression associates with poor clinical outcome on endocrine therapy When breast cancer samples from patients with known clinical outcome were examined for PKC-a expression, brown immunostaining was seen within the tumour epithelial cells' cytoplasm and perinuclear region (fig 4) . Staining was heterogeneous, both within samples and between patients, but using a median HScore of .110 (range 0-170) to define substantial PKC-a immunopositivity versus low expression, statistical analysis revealed an association between PKC-a and ER status, with ER 2 disease showing substantially more PKC-a staining than ER + tissues (table 1 and fig 4) . Expression was not significantly related to disease site, menopausal status or grade of tumour but did correlate to quality of response as measured at 6 months' endocrine therapy, with high PKC-a expression related to progressive disease (table 1) . Furthermore, univariate analysis showed a significantly shorter duration of endocrine response in those patients whose tumours were PKC-a positive (median duration of response: PKC-a + 2 months, 95% CI 0.9 to 3.1; PKC-a 2 6 months, 95% CI 2.7 to 9.3; p = 0.003). There was also a significant decrease in survival time from initiation of endocrine therapy in PKC-a positive patients (median survival: PKC-a + 12 months, 95% CI 2.9 to 21.1; PKC-a 2 29 months, 95% CI 22.0 to 36.1; p = 0.03). PKC-a status was not however an independent predictor of survival on therapy (p = 0.86, HR = 0.95, 95% CI 0.5 to 1.7) or duration of response (p = 0.70, HR = 1.13, 95% CI 0.6 to 2.0) by multivariate analysis, controlling for clinicopathological profile (including ER status). (table 2) . There was also no association with site of disease, menopausal status or tumour grade. However, a significant relationship was observed between PKC-d status and quality of response at 6 months on endocrine therapy, with PKC-d positivity associated with response to therapy (table 2). This relationship was retained even after selecting for patients with ER + disease. Univariate analysis confirmed that there was a trend for longer duration of endocrine response to be 
PKC-d expression predicts for endocrine responsiveness PKC-d immunostaining was readily detectable in the tumour epithelial cells' cytoplasm, but again staining was heterogeneous
DISCUSSION
An association between PKC-a overexpression and the ER 2 phenotype has previously been established in cell line models of breast cancer. 13 15 In addition, increases in growth rate, 29 ERK2 expression, 30 basal AP-1 activity, 15 multidrug resistance, 31 and morphological changes 29 32 have been shown to result from PKC-a overexpression. Although a small clinicopathological study (15 pairs of samples) 33 showed PKC-a expression to predict for tamoxifen treatment failure, a 46-sample study showed a down-regulation of PKC-a expression in advanced tumour samples. 18 This study has not only confirmed the relationship between PKC-a expression and ER negativity in breast cancer cell lines (using ER + MCF-7, T47D and ER 2 MDA-MB-231 cells) but also shown an association with ER 2 staining in clinical material, in a larger (70 sample) study.
Cumulatively this study and others, 14 16 have shown a correlation between ER positivity and PKC-d expression in a variety of cell line models. Importantly we also show here a good correlation between PKC-d expression and improved quality and duration of endocrine response in clinical samples. Moreover PKC-d was shown to be an independent predictor of such response even after correcting for ER status.
Interestingly, over-expression of PKC-d in cell line and xenograft models of breast cancer has recently been shown to contribute to anti-oestrogen resistance, 17 which would initially appear to conflict with our findings. However, we have shown that TAM-R cell lines have raised levels of both PKC-a and d versus their responsive parental cells. Careful scrutiny of the published study 17 and other recent studies claiming association between PKC-a expression and tamoxifen resistance, 34 35 reveals that their tamoxifen resistant cell lines also have raised levels of both PKC-a and d, in complete agreement with our results. We have looked at the effect of a and d isoform coexpression on clinical outcome, showing that co-expression of PKC-a and d predicts for a very short duration of endocrine response and survival on endocrine therapy, in keeping with these being endocrine resistant patients. Although after subdivision our sample size is small, our results are fully in keeping with these previous studies 17 34 and importantly also add to them, indicating that it is co-expression of PKC-a and d that is associated with endocrine resistance, both in cell line models and more importantly in clinical samples.
Thus, knowledge of PKC isoform expression could be useful in helping to predict patients' endocrine responsiveness, with expression of PKC-d in the absence of PKC-a predicting for good endocrine response, PKC-a expression in the absence of PKC-d associating with ER negativity, and associated endocrine N These in vitro models emulate the in vivo clinical situation, where high PKC-d expression correlates with endocrine responsiveness, PKC-a expression correlates with ER negativity, and co-expression of PKC-a and d correlates with poor endocrine response and short on-therapy survival times.
